Takeda cuts forecast in tougher environment
This article was originally published in Scrip
Executive Summary
The bellwether of the Japanese pharma industry, Takeda, has cut back its financial guidance for the year ending next March 31st, pointing to the global economic slowdown, unfavourable exchange rates, healthcare cost controls and generic competition.